NEW YORK (GenomeWeb) – Biosensor firm Silicon Kinetics said today it is collaborating with Biosys Technologies, Tokyo University, and St. Marianna University School of Medicine in Japan on a screening project for lung cancer drugs.

Under the terms of the collaboration, the parties will use Silicon Kinetics' Molecular Interaction Kinetics-Mass Spectrometry (MIK-MS) technology to screen and rank inhibitors targeting lung cancer as part of a larger study investigating the progression of lung cancer in non-smoking adults, along with potential personalized treatments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.